Skip to main content

Drug Interactions between Diamox and Flolan

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

acetaZOLAMIDE epoprostenol

Applies to: Diamox (acetazolamide) and Flolan (epoprostenol)

MONITOR: Coadministration of medicines targeting the prostacyclin pathway (e.g., prostacyclin (PGI2), PGI2 analogs, or selective non-prostanoid prostacyclin IP receptor agonists) with diuretics, antihypertensive agents, or other vasodilators may potentiate the hypotensive effects of these agents. The mechanism involves the additive reduction in blood pressure due to the vasodilatory effects of PGI2, PGI2 analogs or selective non-prostanoid prostacyclin IP receptor agonists on the prostacyclin pathway.

MANAGEMENT: While therapies that target the prostacyclin pathway have been used in combination with diuretics, antihypertensives, or other vasodilators in the management of pulmonary arterial hypertension, caution is recommended if they must be administered concurrently. If these drugs are used together, it is generally recommended that blood pressure be measured more frequently until a stable blood pressure pattern is observed. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their doctor if they experience dizziness, lightheadedness, syncope, orthostatic hypotension, or tachycardia. Treatment guidelines should be consulted for the optimum management of pulmonary arterial hypertension.

References

  1. Buchdahl RM, Taylor P, Warner JD "Nebulised ribavirin for adenovirus pneumonia." Lancet 2 (1985): 1070-1
  2. "Product Information. Flolan (epoprostenol)." Glaxo Wellcome PROD (2001):
  3. "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc (2002):
  4. "Product Information. Remodulin (treprostinil)." United Therapeutics Corporation (2002):
  5. "Product Information. Ventavis (iloprost)." Actelion Pharmaceuticals US Inc (2005):
  6. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
  7. Cerner Multum, Inc. "Australian Product Information." O 0
View all 7 references

Switch to consumer interaction data

Drug and food interactions

No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.


Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.